In fiscal 2018, which ended Jan 31, 2018, Betterlife Pharma Inc. used $395,602 of cash from operations, down 10.1% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2019
Oct 31, 2018
|
FY 2018
Jan 31, 2018
|
FY 2017
Jan 31, 2017
|
FY 2016
Jan 31, 2016
|
FY 2016
Jan 31, 2015
|
FY 2012
Jan 31, 2013
|
FY 2011
Jan 31, 2012
|
|---|---|---|---|---|---|---|---|
| Operating | |||||||
| Depreciation and amortization |
—
|
—
|
—
|
0
|
0
|
—
|
—
|
| Stock-based compensation |
—
|
0
-99.0%
|
5
-15.2%
|
6
|
—
|
—
|
0
|
| Operating cash flow |
-4
-1154.9%
|
-0
-10.1%
|
-0
-660.6%
|
-0
|
-0
|
-0
+76.7%
|
-0
|
| Financing | |||||||
| Financing cash flow |
5
+1293.1%
|
0
-5.1%
|
0
+702.4%
|
0
|
0
|
0
-75.6%
|
0
|
| Ratios | |||||||
| Cash conversion |
—
|
—
|
—
|
—
|
—
|
-0.09x
|
-0.10x
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BETRF (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- British Columbia, Canada
- Headquarters
- Vancouver, British Columbia, Canada
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1464165
- Former names
- Pivot Pharmaceuticals Inc. (until Dec 3, 2019); Neurokine Pharmaceuticals Inc. (until Mar 26, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.